events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Search
Login
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Login
News and Community
Astrazeneca
,
Daiichi Sankyo
,
Datroway
,
Metastatic Triple-negative Breast Cancer
,
Tropion-breast02
,
Us Food And Drug Administration
May 25, 2026
FDA Approves DATROWAY in the US as First TROP2-directed Antibody Drug Conjugate for Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
Adjuvant Therapy
,
Astrazeneca
,
Daiichi Sankyo
,
Destiny-endometrial02
,
Endometrial Cancer
,
Enhertu
,
Future Of Oncology
,
Her2
,
Phase 3 Trial
December 22, 2025
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Started as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Load More
